VYNT News and Press, Vyant Bio Inc. From 08/11/21

CHERRY HILL, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and onc...

CHERRY HILL, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging leader in novel drug discovery, is pleased to announce that Jay Roberts, Chief Executive Officer, will present at A.G.P.’s Virtu...

The USPTO has issued Vyant Bio's ([[VYNT]] -0.4%) wholly-owned subsidiary, StemoniX, US Patent No. 11054408, titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids”. The patent covers a unique approach to applying human-induced Pluripotent Stem Cells...

CHERRY HILL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging leader in novel drug discovery technologies, announced today that its wholly-owned subsidiary, StemoniX, Inc. (“StemoniX&#...

Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...

In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...

Political change along with updated White House priorities have certainly created a need to review investment portfolios. As the national focus shifts from one area of fulfilling citizens' wants and needs to another, some industries are getting more attention while others are put on “hi...

Vyant Bio (VYNT): Q1 Cash and cash equivalents totaled approximately $33.1 million as of March 31, 2021.Revenue of $0.22M (+29.4% Y/Y)Press Release For further details see: Vyant Bio reports Q1 results

Cherry Hill, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is an innovative biotechnology company focused on partnering with pharmaceutical and other biotechnology companies to identify novel and repurposed therapeutics through the inte...

Discovery DISCK +24% on definitive agreement with AT&T.Aerpio Pharmaceuticals ARPO +20% on merger deal with Aadi Bioscience.Nuvve Holding Corp. (NVVE) +16%.Aterian (ATER) +13%.Net Element (NETE) +13%.Mind Medicine MNMD +12% on receiving FDA Type C meeting res...